Biomarkers have become an integral component of the treatment landscape for an increasing number of oncology indications. Patients’ biomarker status often directs prescription choice in malignant melanoma, colorectal cancer, and ovarian cancer. When incorporated into standard clinical care, biomarker-driven therapies offer specific subpopulations of patients the potential for higher response rates and improved survival, albeit often at a high price. We explore the drivers of and barriers to the use of biomarker-based therapies and the impact of reimbursement policies on the use of these therapies. We also evaluate surveyed medical oncologists’ and surveyed payers’ prescriptions of emerging biomarker-driven therapies to treat these solid-tumor indications.

QUESTIONS ANSWERED

· What factors largely influence payers’ reimbursement decisions for biomarker-driven therapies in malignant melanoma, colorectal cancer, and ovarian cancer? What restrictions do they impose?

· Do access and reimbursement challenges differ by indication, and how well established are biomarkers in each indication?

· What impact do reimbursement and access have on oncologists’ decisions to prescribe biomarker-driven therapies?

· What are payer opinions of emerging agents, and how will oncologists’ prescribing patterns change with the launch of new therapies?

GEOGRAPHY: United States.

PRIMARY RESEARCH: Survey of 101 U.S. medical oncologists and 31 U.S. managed care organization (MCO) pharmacy directors and medical directors (PDs/MDs).

KEY DRUGS COVERED: Avastin, Erbitux, Vectibix, Opdivo, Keytruda, Yervoy, Zelboraf, Tafinlar, Mekinist, Cotellic, Braftovi, Mektovi, Lynparza, Zejula, Rubraca

CONTENT HIGHLIGHTS:

  • Executive Summary
  • Reimbursement
  • Access and prescribing.
  • Special topic: Market Access Outlook for biomarkers testing
  • Opportunities and challenges for emerging therapies.

Table of contents

  • Biomarkers In Oncology - Access & Reimbursement - Detailed, Expanded Analysis (US) Biomarkers In Oncology
    • Access & Reimbursement | Biomarkers in Oncology | US | December 2020

Author(s): Neela Rambaruth

Related Reports

Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

View Details

Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)

Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence...

View Details

Prostate Cancer - Epidemiology - Mature Markets Data

DRG Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We repor...

View Details

Prostate Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Hormone Sensititve

The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval...

View Details